CytoMed Therapeutics

Company snapshot

Incorporated in 2018, CytoMed Therapeutics (NASDAQ: GDTC) was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s national research and development agency in the public sector. CytoMed is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel, allogenic off-the-shelf cellular immunotherapies for the treatment of human

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CytoMed Therapeutics. Not investment advice.

• Peer + 0 momentum

  Bristol Myers Squibb

  TA overlap score 28

Recent activity

Latest pipeline, patent, and corporate events for CytoMed Therapeutics.

1. Jun 8, 2026 Clinical update

   CTM-N2D-102 — Phase 1

2. Jun 8, 2026 Clinical update

   CTM-N2D — Phase 1

3. Jun 8, 2026 Clinical update

   human Mesenchymal Stem Cell (MSC) infusion therapy — Phase 1

4. Jun 8, 2026 Clinical update

   Human Umbilical Cord derived MSCs — Phase 2

5. Sep 26, 2006 Patent grant

   Enriched platelet wound healant

View all clinical trial activity →

• What is CytoMed Therapeutics?

  CytoMed Therapeutics is a pharma organization headquartered in 1 COMMONWEALTH LANE, U0, SG. It trades on NYSE under ticker GDTC. Primary therapeutic focus areas include Colorectal Cancer, Cancer, Aging Well, Lupus Nephritis. NovaPharmaNews links 4 clinical program(s), 0 drug prof

• Is CytoMed Therapeutics publicly traded?

  Yes. CytoMed Therapeutics is listed with ticker GDTC on NYSE per SEC EDGAR records linked on this profile.

• What drugs does CytoMed Therapeutics develop or market?

  We link 12 drug profile(s) where CytoMed Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cytomed-therapeutics-ltd#company-drugs.

• What are the latest developments for CytoMed Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CytoMed Therapeutics focus on?

  CytoMed Therapeutics focuses on Colorectal Cancer, Cancer, Aging Well based on our analysis of their pipeline programs and drug development activities.